These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9072935)

  • 1. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians.
    Coley CM; Barry MJ; Fleming C; Fahs MC; Mulley AG
    Ann Intern Med; 1997 Mar; 126(6):468-79. PubMed ID: 9072935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians.
    Coley CM; Barry MJ; Fleming C; Mulley AG
    Ann Intern Med; 1997 Mar; 126(5):394-406. PubMed ID: 9054286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The benefit and cost of prostate cancer early detection. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.
    Littrup PJ; Goodman AC; Mettlin CJ
    CA Cancer J Clin; 1993; 43(3):134-49. PubMed ID: 7683964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost analyses of prostate cancer screening: frameworks for discussion. Investigators of the American Cancer Society-National Prostate Cancer Detection Project.
    Littrup PJ; Goodman AC; Mettlin CJ; Murphy GP
    J Urol; 1994 Nov; 152(5 Pt 2):1873-7. PubMed ID: 7523734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
    Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P;
    Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force.
    Harris R; Lohr KN
    Ann Intern Med; 2002 Dec; 137(11):917-29. PubMed ID: 12458993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for prostate cancer. A decision analytic view.
    Krahn MD; Mahoney JE; Eckman MH; Trachtenberg J; Pauker SG; Detsky AS
    JAMA; 1994 Sep; 272(10):773-80. PubMed ID: 7521400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voluntary screening program for prostate cancer: detection rate and cost.
    Abramson N; Cotton S; Eckels R; Baldock J
    South Med J; 1994 Aug; 87(8):785-8. PubMed ID: 7519789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
    Nichol MB; Wu J; Huang J; Denham D; Frencher SK; Jacobsen SJ
    BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for prostate cancer.
    Ilic D; O'Connor D; Green S; Wilt T
    Cochrane Database Syst Rev; 2006 Jul; (3):CD004720. PubMed ID: 16856057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
    Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
    PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
    Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
    Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A literature review of cost-effectiveness analyses of prostate-specific antigen test in prostate cancer screening.
    Garg V; Gu NY; Borrego ME; Raisch DW
    Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):327-42. PubMed ID: 23763530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The socioeconomic implications of prostate-specific antigen screening.
    Benoit RM; Naslund MJ
    Urol Clin North Am; 1997 May; 24(2):451-8. PubMed ID: 9126243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
    Krahn MD; Coombs A; Levy IG
    CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer screening: what we know and what we need to know.
    Kramer BS; Brown ML; Prorok PC; Potosky AL; Gohagan JK
    Ann Intern Med; 1993 Nov; 119(9):914-23. PubMed ID: 7692780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.
    Lin K; Lipsitz R; Miller T; Janakiraman S;
    Ann Intern Med; 2008 Aug; 149(3):192-9. PubMed ID: 18678846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
    Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
    Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
    J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.